Atossa Therapeutics (ATOS) vs Kyntra Bio (KYNB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kyntra Bio (KYNB) has outperformed Atossa Therapeutics (ATOS) over the past year, losing 47.7% versus a loss of 83.8%. Over five years, ATOS leads with a -94.3% price change compared with -97.8% for KYNB. Atossa Therapeutics is the larger company by market cap ($24.1 million vs $24.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATOS | KYNB |
|---|---|---|
| Share price | $2.42 | $5.96 |
| Market cap | $24.15M | $24.13M |
| 1-day change | -1.63% | -1.32% |
| YTD return | -72.20% | -32.12% |
| 1-year return | -83.76% | -47.72% |
| 5-year return | -94.27% | -97.84% |
| EPS (TTM) | $-4.45 | $-7.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.35 | $11.65 |
| 52-week low | $1.70 | $5.62 |
| Distance from 52-week high | -87.49% | -48.84% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +685.12% | +565.60% |
| Average volume | 64.15K | 18.32K |
| Shares outstanding | 9.98M | 4.05M |
| Employees | 16 | 34 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KYNB has outperformed ATOS by 36.0 percentage points over the past year.
About Atossa Therapeutics
ATOS stock →Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
Healthcare · Biotechnology · 16 employees
About Kyntra Bio
KYNB stock →Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
Healthcare · Biotechnology · 34 employees
ATOS vs KYNB FAQ
Which is bigger, Atossa Therapeutics or Kyntra Bio?
Atossa Therapeutics (ATOS) is larger, with a market capitalization of $24.15M compared with $24.13M for Kyntra Bio (KYNB).
Which stock has performed better over the past year, ATOS or KYNB?
KYNB returned -47.72% over the past 12 months, compared with -83.76% for ATOS (price return, excluding dividends). Past performance does not predict future results.
Are Atossa Therapeutics and Kyntra Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.